Hansa Biopharma
Sweden - LundPharmaceutical
Focus: Hansa Biopharma is a Swedish public biopharmaceutical company specializing in novel immunomodulatory enzymes targeting transplantation and acute autoimmune diseases. The company operates as a clinical-stage biotech with a focused pipeline centered on IgG-degrading enzymes.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
6+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at Hansa Biopharma?
AI assessmentBest fit for scientists/clinicians seeking late-stage biotech upside in a specialized immunology space, but hiring constraints and heavy Phase 3 dependence warrant due diligence on funding runway and post-approval commercialization plans.
Why Work Here
- Lead role in Phase 3 programs: Imlifidase has two Phase 3 indications (kidney transplantation in highly sensitized patients and anti-GBM disease) offering near-term catalysts and publication opportunities.
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Imlifidase administered in the ConfIdeS study
Kidney Transplantation in Highly Sensitized PatientsClinical Trials (1)
NCT05714514Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
N/AHelp build intelligence for Hansa Biopharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.